The Treat-to-Target Trial
MCMatthew C. RiddleJRJulio RosenstockJGJohn GerichOBon behalf of the Insulin Glargine 4002 Study Investigators
Oregon Health & Science University · Dallas Diabetes Research Center · +1 more institution
Indexed incrossrefpubmed
Abstract
OBJECTIVE: To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7% HbA(1c). RESEARCH DESIGN AND METHODS: In a randomized, open-label, parallel, 24-week multicenter trial, 756 overweight men and women with inadequate glycemic control (HbA(1c) >7.5%) on one or two oral agents continued prestudy oral agents and received bedtime glargine or NPH once daily, titrated using a simple algorithm seeking a target fasting plasma glucose (FPG)
Citation impact
1,474
total citations
- FWCI
- 35.26
- Percentile
- 100%
- References
- 29
Citations per year
Authors
4- MCMatthew C. RiddleCorresponding
Oregon Health & Science University
- JRJulio Rosenstock
Dallas Diabetes Research Center
- JGJohn Gerich
University of Rochester Medical Center
- OBon behalf of the Insulin Glargine 4002 Study Investigators
Topics & keywords
Topics
Keywords
- Medicine
- Hypoglycemia
- Insulin glargine
- Bedtime
- Internal medicine
- Glycemic
- Diabetes mellitus
- Type 2 diabetes
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.